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patients, since impaired immunity is presumed to be due not only to the 
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management of metastatic solid tumors, with the introduction of immune 
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Dear Dr. Christian Rolfo, 
 
as per our pre-sumbission inquiry, we are submitting to your Journal a systematic review about the issue of 
influenza vaccination during immunotherapy with immune checkpoint inhibitors in patients affected by 
advanced solid tumors. 
 
This hot topic currently still represents an unmet clinical need, that we hope to address with with 
prospective data in the next years. In the meanwhile, we summarized and commented the available 
evidence, to support a reasonable clinical recommendation. 
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Influenza vaccination is recommended for advanced cancer patients, since impaired immunity is presumed to 
be due not only to the tumor itself but also to immunosuppressive treatments, such as chemotherapy and 
radiotherapy. The recent advances in the systemic management of metastatic solid tumors, with the 
introduction of immune checkpoint inhibitors for several indications in clinical practice, has re-actualized 
simple clinical issues, such as the vaccinal recommendations and counseling, for which common sense is not 
enough to support pragmatic choices. In the present review, we summarized the evidence about influenza 
vaccine administration during immune checkpoint blockade, emphasizing the need of prospective data to 
definitely guide our advices to a growing group of cancer patients. 
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Influenza is an acute respiratory syndrome caused by infection by seasonal influenza viruses (type A, B and 
C), affecting the respiratory tract and including both respiratory and systemic symptoms, such as fever, 
myalgia, headache, cough, chills, nasal congestion and sore throat. Influenza A and B viruses cause seasonal 
epidemics on winter, while type C infection is milder and occurs less frequently [1]. Complications of 
influenza, mostly due to bacterial superinfection, include pneumonia (which is the major and often the most 
severe), but also otitis media and exacerbation of chronic respiratory disease. The major morbidity associated 
with influenza includes the worsening of chronic health conditions, especially in frail patients who are 
classified at high-risk due to their underlying situations: elderly age, pregnancy, chronic diseases, cancer [2]. 
People with solid cancers undergoing chemotherapy are at increased risk of influenza-related complications, 
due to their impaired cell-mediated and antibody-mediated immunity and, particularly in the case of lung 
cancer, to the frailty of the respiratory system commonly existing in these patients [3]. Indeed, a low absolute 
lymphocyte count has been reported as an independent predictor of influenza-related pneumonia [4]. On the 
other side, neutropenia, that is the main immune impairment in cancer patients treated with chemotherapy, is 
associated with a higher risk of bacterial infections rather than viral infections. Therefore, despite a likely 
similar probability to develop influenza, patients with neutropenia are more prone to higher rates of 
influenza-related bacterial complications compared to the general population and to higher influenza-related 
hospitalization rates and higher mortality, as well, associated with a reported lethality rate of 9% [5]. 
Worthwhile, influenza and its complications may also reduce the compliance to treatment, requiring 
discontinuations, thus compromising dose intensity and potentially reducing treatment efficacy [6]. 
The major measure that can be adopted to prevent the influenza infection is currently represented by 
vaccination. A recently updated Cochrane review stated that observational data suggest lower mortality and 
infection‐ related outcomes by the use of influenza vaccination in immunocompromised cancer patients. 
Although limited by the small number of studies, this review showed that the benefits overweigh the 
potential risks when adults with cancer are vaccinated against influenza [2]. Furthermore, so far, 
international and national guidelines recommend influenza vaccination in cancer patients [7-9]. The Centers 




vaccine to individuals at higher risk for medical complications attributable to severe influenza, in particular 
patients who are immunocompromised due to any cause, including immunosuppression caused by 
medications, as well as persons who live with or care for such patients. The Infectious Diseases Society of 
America (IDSA), in the 2013 Clinical Practice Guideline, stated that patients with solid tumor malignancies 
should receive inactivated influenza vaccine annually. 
The current advent of the new immunotherapy with immune checkpoint inhibitors (CKI), recently approved 
with multiple indications for advanced cancer patients [10-11], overturned all our certainties about 
traditionally “simple” issues, such as the concomitant administration of common medications: antibiotics, 
corticosteroids, and even vaccines [12-14]. On the other hand, the influenza-related morbidity and mortality 
of cancer patients treated with anti-PD-1/PD-L1 CKIs have not been explored yet. Currently, no solid data 
support the efficacy of influenza vaccination administration in this subgroup of patients since prospective 
evidence about its safety, its clinical efficacy and its possible interactions with CKIs are still unavailable. 
The present systematic review aims at summarizing the evidence emerged about this issue, mostly coming 
from retrospective experiences and needing of confirmation by prospective data. 
 
MATERIALS AND METHODS 
PRISMA guidelines were followed for the present systematic review [15]. A systematic assessment of 
literature and peer-reviewed presentations was performed by searching PubMed (MEDLINE) and major 
oncology meeting (American Society of Clinical Oncology, www.ASCO.org and European Society for 
Medical Oncology, www.ESMO.org) resources, from the database inception until December 5, 2018. The 
references of the included article were also reviewed for any further potential publication. Two authors 
independently performed the search, to increase accuracy. 
The following keywords were used: (“influenza vaccination” or “flu vaccination” or “influenza vaccine”) 
and (“immune checkpoint inhibitors” or “immunotherapy”) and “cancer patients”. Publications not primarily 
published in English were excluded. All types of original clinical studies were included. Automatic filters 




text of the selected publications was obtained, and the content was then tabulated and summarized by one 
author for the final selection. Any study reporting or considering the use of influenza vaccination during 
therapy with CKI was included. All types of endpoint about efficacy and safety of the vaccine, or about its 
interactions with CKI, were considered. 
 
RESULTS 
Despite the wide and well-documented literature about the use of vaccines for immunocompromised 
patients, enriched by at least three randomized controlled trials, the new oncological population treated with 
CKI is not yet considered in the currently available studies [2]. Table 1 summarizes the literature search 
results. Currently, there are no reliable data to support the use of split vaccines during cancer 
immunotherapy; the safety and the efficacy of the vaccine during CKI therapy are not specifically proven. 
Patient counseling in this setting is therefore not based on reliable scientific evidence, but until now only on 
clinical common sense. Only based on the pharmacological characteristics of CKI antibodies, influenza 
vaccination has been considered as potentially safe in patients treated with cancer immunotherapy. 
 
Retrospective studies 
Only few retrospective studies are currently available in the literature on this topic. 
Looking for explorative data, our group conducted the first retrospective study (the INVIDIa study), 
collecting preliminary evidence about efficacy and compatibility of flu vaccination with CKI therapy in 
cancer patients. The INVIDIa study was the only exploring the clinical efficacy of influenza vaccination 
[16]. It was a multicenter study, conducted with the aim of exploratively addressing the unmet issue of the 
counseling about influenza vaccination for cancer patients treated with immunotherapy, by enrolling 
consecutive advanced cancer outpatients receiving CKI during the 2016-2017 influenza season. Of the 300 
patients included in the analysis, 79 received influenza vaccination. The incidence of ILI was 24.1% among 
vaccinated patients vs 11.8% among controls; OR =2.4 (95% CI = 1.23 - 4.59; p = 0.009). The clinical 




6.1% among unvaccinated, OR = 9.28 (95% CI = 2.77 - 31.14), p<0.0001. However, the severity of 
influenza syndrome was mild irrespective of the vaccination, with no lethal cases in the overall population. 
No statistically significant differences were seen in terms of objective response rate, disease control rate and 
time to treatment failure with CKI therapy between vaccinated and control patients, respectively, or between 
patients developing ILI or not in the overall study population. Interestingly, subgroup data suggested that the 
inefficacy of influenza vaccination was less pronounced for lung cancer patients. Moreover, despite data for 
overall survival (OS) were immature, a statistically significant positive correlation with the vaccine 
administration and/or ILI development was demonstrated in this subgroup: 1-year OS was 86.7% (95% CI = 
75.7-97.7) for the vaccine/ILI group versus 66.7% (95%CI = 53.6-79.8), p = 0.02; this finding was 
confirmed at the multivariate analysis. Thus, the increased morbidity of influenza in vaccinated patients did 
not negatively impact the clinical outcome. We hypothesized that CKI treatment may have been responsible 
for greater immunocompetence against the infection and its bacterial complications since the severity and 
lethality of ILI were prevented in patients treated with CKI irrespective of the vaccine administration [19]. 
On the other hand, a possible enhanced aberrant T cell response could paradoxically contribute to the ILI 
immunopathology and the observed increased incidence of infection in vaccinated CKI-treated patients [17]. 
As far as the impact on the anticancer treatment outcome is concerned, we hypothesized that vaccine-
induced or influenza-induced antigen stimulation may have a similar positive effect on the cell-mediated 
immune response to CKI treatment, acting as a synergic immunogenic stimulus. In the INVIDIa study 
population, the immune activation given by the viral particles of the split vaccine, and possibly by the natural 
infection itself, may have been contributed to the antitumor effect of immunotherapy [18]. 
The results of three subsequent retrospective analyses about the impact of the vaccine on the outcome of 
cancer patient treated with immunotherapy, were reported at the 2017 and 2018 annual meeting of the 
American Society of Clinical Oncology (ASCO). Some of their results confirmed, as it was in the INVIDIa 
study, an improvement in OS in vaccinated patients, regardless of the clinical efficacy of the vaccine, which 
was not specifically tested [19-21]. 
A further retrospective study, recently conducted on a prospective population of 127 patients with lung 




differences in terms of immune-related adverse events (irAEs) between the vaccinated cohort compared with 
that of non-vaccinated patients [22]. The authors reported an incidence of irAEs of 26% and 22%, 
respectively in the vaccinated and unvaccinated patients (OR = 1.20, 95% confidence interval [CI] 0.51-
2.65), and a respective rate of severe irAEs of 7% and 4% (OR = 2.07, 95% CI 0.28-15.43). In this series, 
vaccination showed no correlation with the rate of therapy discontinuation, nor with the objective response to 
cancer treatment [22]. 
 
Prospective studies 
No prospective studies assessing the clinical efficacy of influenza vaccination during immunotherapy with 
CKI in cancer patients were found. 
The phase II study CA184-004, providing the only formal demonstration of the serological efficacy of 
vaccines during immunotherapy with CKI, demonstrated humoral responses to influenza vaccine in patients 
with melanoma treated with ipilimumab (anti-CTLA-4 monoclonal antibody) [23]. However, no data were 
provided on the clinical efficacy of the influenza vaccine, in terms of incidence of influenza-like syndrome 
(ILI) and efficacy of the anticancer therapy in vaccinated subjects. In detail, the study evaluated the 
administration of the tetanus vaccine ten days before and of influenza and anti-pneumococcal vaccines a 
week after the start of systemic therapy with ipilimumab in patients with advanced melanoma. Humoral 
responses were tested at baseline and on the seventh week of therapy. The majority of patients had an 
increase in levels of specific antibodies (i.e., humoral response) against influenza A and B virus antigens, 
which were absent in unvaccinated patients. No difference was observed in terms of humoral response in the 
group of patients receiving 3 mg/kg of ipilimumab compared to those receiving 10 mg/kg [16]. 
On the contrary, very few data are currently available about the same issue in patients receiving nivolumab 
or other anti-PD-1 / anti-PD-L1 monoclonal antibodies. Influenza vaccination was allowed at any time 





Recently, a small Swiss prospective study suggested that seasonal influenza vaccination could increase the 
rate of serious irAEs in patients treated with anti-PD-1 / PD-L1 antibodies. This evidence, of limited strength 
due to the small sample size (23 patients) and the lack of a control group for the toxicity data, instilled the 
first doubt of a possible contraindication of influenza vaccination in patients treated with CKIs. The 
administration of the vaccine was associated with a rather high rate of irAEs: over half of patients had 
adverse events of any grade and 26% of patients reported severe irAEs. The researchers suggested, as a 
possible explanation, that patients receiving CKI have a hyperactivated state of the immune system and this 
could induce excessive responses by the vaccine, thus triggering irAEs with greater frequency and intensity 
than expected [25]. Interestingly, the authors compared the antibody titers against three viral antigens of 
cancer patients undergoing PD-1 blockade with healthy age-matched controls, finding a higher and faster 
humoral response in cancer patients. These data may support the hypothesis that patients treated with CKI 
are more immunocompetent since immunotherapy normalizes cellular and humoral immunity [25]. 
 
CONCLUSIONS 
The scarce and controversial evidence about influenza vaccination during anticancer therapy with CKI 
confirms the need of more robust data on the safety of vaccine during immunotherapy and, consequently, on 
its advisability in a population where its usefulness has not yet specifically been proven. Although the safety 
of the vaccine in immune-treated patients has not yet been demonstrated by prospective data, it is known that 
major complications can ensue from infections in cancer patients, especially in case of lung cancer or 
respiratory impairment. Currently, a reliable literature in support of this issue is still lacking. 
On the basis of this unmet clinical need, prospective ad hoc studies are eagerly awaited. Our group is 
currently conducting a large, multi-center prospective trial, the INVIDIa-2 study, which will collect data 
during the flu season 2019-2020, aiming at providing reliable results to provide recommendations about 





Considering the currently reported findings, CKI-treated cancer patients should be advised about the risk of 
possible clinical ineffectiveness of the influenza vaccine. On the other hand, patients could be reassured that 
the vaccine would not have a negative impact on their anticancer immunotherapy, although no safety 
prospective data are currently available to rule out possible complications. 
Although the uncertainty about the safety of the vaccine in these patients, the evidence for a longer survival 
observed in vaccinated patients across the available studies irrespective of the clinical efficacy of the 
vaccine, could not support an abstentionist attitude. Indeed, a synergy in the efficiency of the immune system 
against the “non-self” whether of viral or tumor origin, could play a role during CKI and following 
vaccination. 
Pending prospective data, the only proper recommendation is currently in favor of a prudential and 
personalized approach, entailing the consideration of individual patient risk factors, such as age, 
comorbidities, metastatic sites and organs involved, functional respiratory impairment. In those patients for 
whom the risk of serious complications from influenza infection is expected to be high, vaccination should 
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Table 1 – Available data from studies describing the impact of influenza vaccination in advanced 
cancer patients undergoing immunotherapy with immune checkpoint inhibitors. 
Author and 
year 

























Schenk EL 2017 
(abstract) [19] 







Retrospective 534 + NA + ++ + 
Chong CR 2018 
(abstract) [21] 
Retrospective 147 NA NA NA NA + 
Wijn DH 2018 
[22] 
Retrospective 127 NA NA + NA + 
Weber JS 2012 
[23] 
Prospective 82 NA ++ NA NA NA 
Laubli H 2018 
[25] 
Prospective 23 NA +++ NA NA _ 
NA = not assessed; + / ++ / +++ and - / -- / --- values were assigned basing on the consensual opinion of the authors 
about the strength of the data reported in the studies, with the clear limitations of their heterogeneity and of indirect 
comparisons. 
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